THC

TORONTO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, congratulates Tenet Fintech Group Inc. (“Tenet”) on its second quarter 2026 financial results. Tenet is an innovative analytics service provider and the owner and operator of the Cubeler Business Hub. Tenet’s second quarter 2026 financial results are available in its recently issued press release. ThreeD is a long-standing investor in Tenet. As of the date hereof, ThreeD holds 12,100,000 common shares of Tenet, warrants to acquire an additional 17,000,000 common shares of Tenet and a convertible debenture of Tenet for a principal amount of $150,000. About ThreeD Capital Inc. ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem. For further information: Jakson InwentashVice President [email protected] Phone: 416-941-8900 ext 107 The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. Forward-Looking Statements This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Often, but not always, these forward looking statements can be identified by the use of words such as “believe”, “believes”, "estimate", "estimates", "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "upgraded", "offset", "limited", "contained", "reflecting", "containing", "remaining", "to be", "periodically", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes the expectations reflected in these forward-looking statements are reasonable, there can be no assurance they will prove accurate. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Toronto, Ontario--(Newsfile Corp. - August 26, 2026) - Tenet Fintech Group Inc. (CSE: PKK) (OTC Pink: PKKFF) ("Tenet" or the "Company"), today announced its financial results and operating highlights for the three-month period ended June 30, 2026. Tenet reported revenue of $52,785,664 for the quarter, compared to $433,570 in the second quarter of 2025, and a net profit of $2,662,136 for the second quarter of 2026, compared to a net loss of $1,828,881 in Q2-2025. All amounts in this news release are in Canadian dollars unless otherwise indicated. Q2-2026 Key Financial Figures Total Revenue of $52.78 million Net Profit of $2.66 million Q2-2026 Operating Highlights The significant year-over-year increase in revenue from Q2-2025 to Q2-2026 and the solid profitability numbers signal the completion of the Company's turnaround following the 2023 proxy battle that threatened its very existence. The Company spent the better part of the last three years following the 2023 events to: 1) re-establish itself as a technology driven supply-chain transaction facilitator in China; 2) simplify and limit its business activities to facilitating supply-chain transactions and gathering small and medium-sized business data; and 3) transition its business model from primarily generating transaction fee-based revenue to a predominantly recurring revenue model by providing economic intelligence subscription services. The second quarter results reflect the work put in by management during that period. Although work remains to be done on the data-derived subscription revenue front, with the Company's supply-chain business providing a strong revenue base with gross profit margins of 8% to 10% as of Q2-2026, Tenet believes it is financially well positioned for the roll out of its data-derived products, for which the Company is anticipating gross profit margins of 70% to 80%. Full details of the Company's second quarter 2026 financial results can be found in the Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the three-month and six-month periods ended June 30, 2026, and June 30, 2025, which are available under the Company's profile at www.sedarplus.ca. Q2-2026 Results Q&A and Full Year Outlook for 2026 Tenet CEO Johnson Joseph will answer questions from shareholders related to the Company's Q2-2026 financial results in a Q&A interview and will share his perspective on the Company's business plan for the rest of 2026. Shareholders are invited to read the Company's MD&A prior to sending their questions related to these subjects to the Company. Questions related to the Q2-2026 results and Tenet's outlook for 2026 received by 9:00pm EDT on August 31, 2026 to [email protected] or [email protected] will be answered to the extent that they can be answered in compliance with Canadian securities regulations. The results of the Q&A interview will be posted on the Company's website by 5:00pm EDT on September 4, 2026. About Tenet Fintech Group Inc.: Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial intelligence (AI) companies. All references to Tenet in this news release, unless explicitly specified, include Tenet and all its subsidiaries. Tenet's subsidiaries offer various analytics and AI-based products and services to businesses, capital markets professionals, government agencies and financial institutions either through or by leveraging data gathered by the Cubeler Business Hub, a global ecosystem where analytics and AI are used to create opportunities and facilitate B2B transactions among its members. Please visit our website at: https://www.tenetfintech.com/. For more information, please contact: Tenet Fintech Group Inc.Mayco Quiroz, Chief Operating Officer514-340-7775 ext.: [email protected] CHF Capital MarketsCathy Hume, CEO416-868-1079 ext.: [email protected] Follow Tenet Fintech Group Inc. on social media:X: @Tenet_FintechFacebook: @TenetLinkedIn: TenetYouTube: Tenet Fintech Forward-looking information Certain statements in this press release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors which may cause actual results, performance or achievements of Tenet to be materially different from the outlook or any future results, performance or achievements implied by such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements. Important risk factors that could affect the forward-looking statements in this news release include, but are not limited to, holding company with significant operations in China; general economic and business conditions, including factors impacting the Company's business in China such as pandemics and COVID-19; legislative and/or regulatory developments; Global Financial conditions, repatriation of profits or transfer of funds from China to Canada, operations in foreign jurisdictions and possible exposure to corruption, bribery or civil unrest; actions by regulators; uncertainties of investigations, proceedings or other types of claims and litigation; timing and completion of capital programs; liquidity and capital resources, negative operating cash flow and additional funding, dilution from further financing; financial performance and timing of capital; and other risks detailed from time to time in reports filed by Tenet with securities regulators in Canada. Reference should also be made to Management's Discussion and Analysis (MD&A) in Tenet's annual and interim reports, Annual Information Form, filed with Canadian securities regulators and available via the System for Electronic Document Analysis and Retrieval (SEDAR+) under Tenet's profile at www.sedarplus.ca, for a description of major risk factors relating to Tenet. Although Tenet has attempted to identify certain factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements reflect information as of the date on which they are made. The Company assumes no obligation to update or revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities laws. In the event the Company does update any forward-looking statement, no inference should be made that the Company will make additional updates with respect to that statement, related matters, or any other forward-looking statement. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311559

Tenet Healthcare Corporation’s THC second-quarter 2026 results show why its Hospital Operations segment remains an important earnings driver. Despite pressure from weaker exchange enrollment, the segment delivered stronger volumes, better revenue per patient and meaningful margin improvement, giving investors a reason to remain optimistic about the earnings outlook. Hospital adjusted admissions increased 2.6% year over year, while revenue per adjusted admission rose 3.3%. This combination is encouraging because THC is benefiting from both healthy patient demand and a better mix of services. The improvement in revenue per admission reflects its focus on higher-acuity care, while stronger commercial revenues are helping support top-line growth. The hospital segment is translating this momentum into stronger profitability. Hospital adjusted EBITDA jumped 22.3% to $762 million, significantly faster than revenue growth, while the margin expanded to 18% from 15.6% a year ago. This suggests its cost-management efforts are helping convert operational growth into stronger profits. However, exchange weakness remains a caution. Exchange revenues fell 17% in the second quarter of 2026 and are expected to remain under pressure. Still, continued volume growth, better acuity and cost discipline should help offset some of that weakness. The company’s $2.67-$2.81 billion 2026 Hospital adjusted EBITDA guidance signals confidence in continued underlying improvement, positioning the segment as a potential near-term tailwind for THC’s earnings. Tenet is not the only one benefiting from healthy demand for hospital care. Healthcare peers, including Universal Health Services, Inc. UHS and HCA Healthcare, Inc. HCA, also reported solid hospital volume and revenue growth in the second quarter of 2026. Universal Health delivered strong hospital performance, with acute-care adjusted admissions rising 2.9%. UHS’ net revenue per adjusted admission increased 3.0%, while same-facility acute-care revenues grew 8.2%, reflecting continued strength across its hospital operations. HCA Healthcare posted solid hospital growth in the second quarter of 2026, with same-facility equivalent admissions increasing 2.7%. HCA’s revenue per equivalent admission also rose 6.4%, pointing to healthy demand and a favorable patient mix. Shares of Tenet Healthcare have gained 56.4% over the past year compared with the industry's 28% growth over the same period. Image Source: Zacks Investment Research From a valuation standpoint, THC trades at a forward price-to-earnings ratio of 13.43X, up from the industry average of 11.28X. THC carries a Value Scoreof A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for THC’s 2026 earnings is pegged at $20.16 per share, implying a 20.1% jump from the year-ago period’s level. Image Source: Zacks Investment Research THC currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature. In this regard, we ran a screener that yielded stocks Centene CNC, Tenet Healthcare THC, Fortinet FTNT, Unity Software U and The Goldman Sachs Group GS as the likely winners on the earnings beat potential. Historically, stocks of companies with solid quarterly earnings (on a nominal basis) tank if they miss or merely meet market expectations. After all, a 20% earnings rise (though apparently looks good) doesn’t tell you if earnings growth has been exhibiting a decelerating trend. Also, seasonal fluctuations sometimes come into play. If a company’s Q1 is seasonally weak and Q4 strong, then it is likely to report a sequential earnings decline. In such cases, growth rates are misleading while judging the true health of a company. On the other hand, after much brainstorming and analysis of companies’ financials and initiatives, Wall Street analysts project earnings of companies. They in fact club their insights and a company’s guidance when deriving an earnings estimate. Thus, outperforming that estimate is almost equivalent to beating the company’s own expectation as well as the market perception. And if the margin of earnings surprise is big, it typically drives the stock higher right after the release. Thus, more than anything else, an earnings surprise can push a stock higher. Now, finding stocks that have the potential to beat on the bottom line may be investors’ dream but not an easy job. One way to do this is to look at the earnings surprise history of the company. An impressive track record in this regard generally acts as a catalyst in sending a stock higher. It indicates the company’s ability to surpass estimates. And investors generally believe that the company will apply the same secret sauce to execute yet another earnings beat in its next release. In order to shortlist stocks that are likely to come up with an earnings surprise, we chose the following as our primary screening parameters. Last EPS Surprise greater than or equal to 10%: Stocks delivering positive surprise in the last quarter tend to surprise again. Average EPS Surprise in the last four quarters greater than 20%: We lifted the bar for outperformance slightly higher by setting the average earnings surprise for the last four quarters at 20%. Average EPS Surprise in the last two quarters greater than 20%: This points to a more consistent surprise history and makes the case for another surprise even stronger. In addition, we place a few other criteria that push up the chance of a positive surprise. Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) rating can get through. Earnings ESP greater than zero: A stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for an earnings beat to happen, as per our proven model. In order to zero in on those that have long-term growth potential and high trading liquidity, we have added the following parameters too: Next 3–5 Years Estimated EPS Growth (Per Year) greater than 10%: Solid expected earnings growth exhibits the stock’s long-term growth prospects. Average 20-day Volume greater than 100,000: High trading volume implies that the stocks have adequate liquidity. A handful of criteria has narrowed down the universe from over 7,700 stocks to only 16. Here are five out of 16 stocks: Centene: The Zacks Rank #1 company has established itself as a national leader in healthcare services. You can see the complete list of today’s Zacks #1 Rank stocks here. The average earnings surprise of CNC for the past four quarters is 151.28%. Tenet Healthcare: The Zacks Rank #1 company is an investor-owned healthcare services company, which owns and operates general hospitals and related healthcare facilities for urban and rural communities in numerous states, and has offices in California and Florida. The average earnings surprise of THC for the past four quarters is 22.70%. Fortinet:The Zacks Rank #1 company is a leader in cybersecurity, driving the convergence of networking and security. The average earnings surprise of FTNT for the past four quarters is 20.34%. Unity Software: The company provides a platform to develop, deploy and grow games and interactive 3D experiences across mobile, PC, console and extended reality. The stock has a Zacks Rank #2. The average earnings surprise of U for the past four quarters is 12.54%. The Goldman Sachs Group: It is a leading global financial holding company providing investment banking, securities, investment management, and consumer banking services to a diversified client base. The stock has a Zacks Rank #1. The average earnings surprise of GS for the past four quarters is 20.42%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Fortinet, Inc. (FTNT) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Unity Software Inc. (U) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Encompass Health Corporation EHC reported second-quarter adjusted earnings per share (EPS) of $1.55, which beat the Zacks Consensus Estimate by 4.7%. The bottom line increased 10.7% year over year. Net operating revenues of $1.6 billion improved 9.6% year over year. The top line marginally beat the consensus mark by 1.5%. The robust results were primarily driven by strong growth in net patient revenue per discharge, supported by solid discharge volumes and contributions from capacity expansion. However, the upside was partly offset by elevated operating expenses, particularly higher salaries, benefits, and general and administrative costs. Encompass Health Corporation price-consensus-eps-surprise-chart | Encompass Health Corporation Quote EHC’s net patient revenue per discharge rose 3.9% year over year and beat the Zacks Consensus Estimate by 2.1%. Total discharges grew 5.6% year over year to 68,895, but missed the consensus estimate by 0.2%. Total operating expenses of $1.3 billion escalated 9.2% year over year due to elevated salaries, benefits, other operating and general & administrative expenses. The figure marginally missed our estimate by 0.9%. Net income climbed 12.2% year over year to $207.4 million in the second quarter. Adjusted EBITDA of $348 million grew 9.2% year over year and surpassed our estimate of $330.2 million. In the first half, Encompass Health opened three new hospitals with beds totaling 139 and added 54 beds across its existing hospitals. Encompass Health exited the second quarter with cash and cash equivalents of $107.7 million, which rose 49.2% from the 2025-end level. Total assets of $7.5 billion increased 5.2% from the 2025-end level. Long-term debt, net of the current portion, amounted to $2.6 billion, which increased 6.2% from that recorded as of Dec. 31, 2025. The current portion of long-term debt totaled $35.9 million. Total shareholders’ equity of $3.4 billion improved 5.8% from the 2025-end figure. EHC generated $595.7 million of net cash from operations in the first half, which improved 6.6% from the prior-year figure. Adjusted free cash flow decreased 9.2% to $370.8 million for the period. Encompass Health bought back 0.7 million shares worth $74.2 million in the second quarter of 2026. As of June 30, 2026, the company had a leftover capacity of around $188 million under its buyback authorization. On July 23, 2026, Encompass Health increased the aggregate common stock repurchase authorization to $1 billion. Management paid out a quarterly cash dividend of 19 cents per share. Net operating revenues are now expected to be between $6.41 billion and $6.49 billion, up from the earlier projection of $6.375-$6.475 billion. This reflected growth over the 2025 reported figure of $5.94 billion. Adjusted EBITDA is now expected to range between $1.365 billion and $1.395 billion, up from $1.27 billion in 2025. The prior guidance was $1.35-$1.38 billion for the metric. Adjusted EPS from continuing operations is projected to be between $6.02 and $6.25, reflecting an increase from $5.45 in 2025. The earlier guidance for the metric was $5.89-$6.11. Adjusted free cash flow is presently forecasted to be in the range of $760-$865 million. Maintenance CAPEX is expected to remain in the range of $225-$240 million. The company still expects to open eight de novo hospitals, adding a total of 389 beds. It plans to add 150 to 200 beds to its existing hospitals. Over the 2023-2027 period, management still aims to inaugurate six to 10 de novos each year, as well as make bed additions in the range of 80-120 every year. It also expects a CAGR of 6-8% in discharges in the same time frame. It also expects to open freestanding hospitals, including remote and satellite locations, with more than 30 beds beginning in 2026. EHC currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation THC, Elevance Health, Inc. ELV and Pediatrix Medical Group, Inc. MD. Here's how they have performed: Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions. Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. ELV’s quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The gains were partly offset by a decline in overall medical membership and higher operating expenses. Pediatrix Medical reported second-quarter 2026 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate by 10.5%. The bottom line increased 18.9% year over year. Net revenues increased 4.1% year over year to $487.8 million. MD’s strong performance was driven by improved cash collection activity and a favorable payor mix, along with contributions from recent acquisitions. However, these gains were partly offset by lower patient volumes and higher operating costs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Encompass Health Corporation (EHC) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Pediatrix Medical Group, Inc. (MD) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Pediatrix Medical Group, Inc. MD reported second-quarter 2026 adjusted earnings per share (EPS) of 63 cents, which beat the Zacks Consensus Estimate by 10.5%. The bottom line increased 18.9% year over year. Net revenues increased 4.1% year over year to $487.8 million. The top line surpassed the Zacks Consensus Estimate by 2.2%. The strong performance was driven by improved cash collection activity and a favorable payor mix, along with contributions from recent acquisitions. However, these gains were partly offset by lower patient volumes and higher operating costs. Pediatrix Medical Group, Inc. price-consensus-eps-surprise-chart | Pediatrix Medical Group, Inc. Quote Same-unit revenues increased 1.9% year over year, which beat our growth estimate of 0.4%. Same-unit revenues from patient service volumes declined 2.1% year over year. Same-unit revenues from net reimbursement-related factors grew 4% year over year. This growth was supported by higher cash collections, increased patient acuity and a slightly better payor mix. This metric exceeded our model estimate of 2.6%. Total operating expenses were $430.9 million, up 5.4% year over year. The figure was higher than our estimate of $415.8 million. The year-over-year increase was primarily due to higher practice salaries and benefits costs, and general and administrative expenses. Practice salaries and benefits totaled $336.1 million, up 3.9% year over year, mainly due to higher same-unit clinical salaries and malpractice expenses. Interest expense decreased 10.5% year over year to $8.2 million. The figure was below our estimate of $8.7 million due to lower interest rates and borrowings. Adjusted EBITDA rose 4.4% year over year to $76.4 million, driven by favorable contributions from recent acquisitions. Pediatrix Medical exited the second quarter of 2026 with cash and cash equivalents of $288.9 million, down from $375.2 million as of Dec. 31, 2025. There were no outstanding borrowings on its revolving credit facility at the end of the quarter. Total assets of $2.1 billion decreased from $2.2 billion at the end of 2025. Total debt, including finance leases, net was $584.2 million, which fell from $597.3 million at the end of 2025. Total shareholders’ equity of $881 million improved from $865.9 million at the end of 2025. MD generated net cash from operations of $126.3 million in the second quarter of 2026 compared with $138.1 million in the prior-year comparable period. During the first half of 2026, the company repurchased 2.8 million shares for $61.7 million. As of June 30, 2026, $104.5 million was available under the buyback program. Management has reaffirmed its guidance for adjusted EBITDA at $280-$300 million for 2026. Net income is now estimated to be between $147.6 million and $162.1 million for 2026. Interest expenses are currently forecasted to be $33.1 million. Income tax expenses are expected to be in the range of $54.5-$60 million. Depreciation and amortization expenses are now estimated to be $24.4 million. Transformational and restructuring-related expenses are anticipated to be $20.4 million. MD currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation THC, Elevance Health, Inc. ELV and UnitedHealth Group Incorporated UNH. Here's how they have performed: Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions. Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. ELV’s quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The gains were partly offset by a decline in overall medical membership and higher operating expenses. UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. UNH’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pediatrix Medical Group, Inc. (MD) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature. In this regard, we ran a screener that yielded The Estee Lauder Companies EL, Boise Cascade BCC, Tenet Healthcare THC, Silicon Motion Technology SIMO and Valero Energy VLO as the likely stock winners on the earnings beat potential. Historically, stocks of companies with solid quarterly earnings (on a nominal basis) tank if they miss or merely meet market expectations. After all, a 20% earnings rise (though it apparently looks good) doesn’t tell you if earnings growth has been exhibiting a decelerating trend. Also, seasonal fluctuations come into play sometimes. If a company’s Q1 is seasonally weak and Q4 strong, then it is likely to report a sequential earnings decline. In such cases, growth rates are misleading while judging the true health of a company. On the other hand, after much brainstorming and analysis of companies’ financials and initiatives, Wall Street analysts project earnings of companies. They in fact club their insights and a company’s guidance when deriving an earnings estimate. Thus, outperforming that estimate is almost equivalent to beating the company’s own expectation as well as the market perception. And if the margin of earnings surprise is big, it typically drives the stock higher right after the release. Thus, more than anything else, an earnings surprise can push a stock higher. Now, finding stocks that have the potential to beat on the bottom line may be investors’ dream but not an easy job. One way to do this is to look at the earnings surprise history of the company. An impressive track record in this regard generally acts as a catalyst in sending a stock higher. It indicates the company’s ability to surpass estimates. And investors generally believe that the company will apply the same secret sauce to execute yet another earnings beat in its next release. In order to shortlist stocks that are likely to come up with an earnings surprise, we chose the following as our primary screening parameters. Last EPS Surprise greater than or equal to 10%: Stocks delivering positive surprise in the last quarter tend to surprise again. Average EPS Surprise in the last four quarters greater than 20%: We lifted the bar for outperformance slightly higher by setting the average earnings surprise for the last four quarters at 20%. Average EPS Surprise in the last two quarters greater than 20%: This points to a more consistent surprise history and makes the case for another surprise even stronger. In addition, we place a few other criteria that push up the chance of a positive surprise. Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) rating can get through. Earnings ESP greater than zero: A stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for an earnings beat to happen, as per our proven model. In order to zero in on those that have long-term growth potential and high trading liquidity, we have added the following parameters too: Next 3–5 Years Estimated EPS Growth (Per Year) greater than 10%: Solid expected earnings growth exhibits the stock’s long-term growth prospects. Average 20-day Volume greater than 100,000: High trading volume implies that the stocks have adequate liquidity. A handful of criteria narrowed down the universe from over 7,700 stocks to only 11. Here are five out of 11 stocks: The Estee Lauder Companies: The Zacks Rank #2 company is one of the world's leading manufacturers and marketers of skin care, makeup, fragrance and hair care products. You can see the complete list of today’s Zacks #1 Rank stocks here. The average earnings surprise of EL for the past four quarters is 39.08%. Boise Cascade: The Zacks Rank #2 (Buy) company is one of the largest wood products manufacturers and a leading United States wholesale distributor of building products, headquartered in Boise, ID. The average earnings surprise of BCC for the past four quarters is 40.83%. Tenet Healthcare: The Zacks Rank #2 company is an investor-owned healthcare services company, which owns and operates general hospitals and related healthcare facilities for urban and rural communities in numerous states, and has offices in California and Florida. The average earnings surprise of THC for the past four quarters is 22.7%. Silicon Motion Technology: Silicon Motion Technology Corporation is a leading developer of microcontroller ICs for NAND flash storage devices. The stock has a Zacks Rank #1. The average earnings surprise of SIMO for the past four quarters is 13.96%. Valero Energy: The company, through its subsidiaries, is a multinational manufacturer and marketer of petroleum-based and low-carbon liquid transportation fuels and petrochemical products. The stock has a Zacks Rank #2. The average earnings surprise of VLO for the past four quarters is 26.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valero Energy Corporation (VLO) : Free Stock Analysis Report The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Silicon Motion Technology Corporation (SIMO) : Free Stock Analysis Report Boise Cascade, L.L.C. (BCC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Tenet Healthcare has delivered a very strong 270.6% return over the past 5 years, so the key issue for investors now is whether the current price still lines up with what the valuation checks suggest about the stock. The 270.6% 5 year return highlights how much expectations have shifted and raises the bar for any further gains to be supported by fundamentals. Recent optimism around revenue growth and margin execution can support the current valuation, while any setback in managing costs or volumes may quickly weigh on what investors are willing to pay. Tenet Healthcare screens as attractively priced on a broad set of metrics, with the valuation checks suggesting the stock looks undervalued in 5 of 6 areas. The issue now is whether Tenet Healthcare's current share price fairly reflects this combination of past returns and a generally supportive valuation profile. Tenet Healthcare delivered 61.2% returns over the last year. See how this stacks up to the rest of the Healthcare industry. The P/E ratio is a useful way to look at Tenet Healthcare because earnings are a key driver of how investors value hospital and healthcare service stocks. Tenet Healthcare currently trades on a P/E of 9.2x, which is well below both the healthcare industry average of about 25.0x and a peer group average of 20.6x. The fair P/E ratio estimate for Tenet Healthcare is 17.4x, which reflects what investors might usually pay given its sector, profitability profile and risks. That is almost double the current multiple, which suggests the market is pricing the stock at a discount to what those fundamentals would typically justify. Despite the reported 2026 earnings beat and raised guidance lifting sentiment recently, the P/E still sits at a sizable gap to industry and peer levels. On the P/E multiple, Tenet Healthcare stock appears undervalued compared with both its tailored fair ratio and the wider healthcare sector. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Tenet Healthcare pick up where the valuation puzzle leaves off and spell out which earnings, growth and margin paths would make the stock look meaningfully higher or lower than today's price. Each Narrative links its number to a clear view of how Tenet Healthcare's growth, profitability and risk profile might evolve. This gives you something specific to revisit as new information comes through on the Community page. Community views on Tenet Healthcare sit far apart, with one side focused on upside from outpatient growth and the other highlighting execution and reimbursement risk. Bull case: 8% undervalued Read the full Bull Case to see why Tenet Healthcare could be undervalued Bear case: 6% overvalued Read the full Bear Case to see why Tenet Healthcare could be overvalued Do you think there's more to the story for Tenet Healthcare? Head over to our Community to see what others are saying! Tenet Healthcare still screens as undervalued on market multiples, with the current P/E sitting well below both sector and peer averages and the tailored fair ratio. The valuation gap now turns on whether earnings quality, margins and balance sheet execution stay strong enough for the market to close some of that discount. For you as an investor, the key question is whether the lower multiple reflects mispricing or a fair penalty for the execution and reimbursement risks highlighted in the bear case. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include THC. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Tenet Healthcare’s second quarter was marked by robust operational execution, with management attributing outperformance to growth in higher-acuity care, disciplined expense controls, and technology-enabled cost management programs. CEO Saum Sutaria emphasized the company’s focus on targeted service line expansion and efficiency initiatives. These efforts enabled Tenet to navigate payer mix shifts and exchange enrollment declines, with management highlighting strong commercial and Medicaid revenue contributions, as well as volume gains in key hospital and ambulatory segments. Is now the time to buy THC? Find out in our full research report (it’s free). Revenue: $5.63 billion vs analyst estimates of $5.42 billion (6.8% year-on-year growth, 3.9% beat) Adjusted EPS: $6.12 vs analyst estimates of $4.26 (43.5% beat) The company lifted its revenue guidance for the full year to $22.2 billion at the midpoint from $21.9 billion, a 1.4% increase Management raised its full-year Adjusted EPS guidance to $21.00 at the midpoint, a 19.8% increase EBITDA guidance for the full year is $4.93 billion at the midpoint, above analyst estimates of $4.66 billion Operating Margin: 26.7%, up from 15.6% in the same quarter last year Same-Store Sales rose 2.6% year on year (0.4% in the same quarter last year) Market Capitalization: $22.19 billion While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Craig Hettenbach (Morgan Stanley) asked for specific examples of cost structure improvements. CEO Saum Sutaria cited “traditional productivity strategies, contract renegotiations, and technology-driven automation,” as well as process improvements in clinical operations and support functions. Benjamin Rossi (J.P. Morgan) questioned the drivers of revenue growth in the ambulatory segment. Sutaria explained the focus on expanding high-acuity service lines, particularly orthopedics, urology, and robotics, and noted ongoing scaling in bariatrics and cardiovascular specialties. Matthew Gillmor (KeyBanc Capital Markets) probed the impact of exchange revenue declines and patient mix. CFO Sun Park clarified that the majority of lost exchange volumes converted to uninsured patients and that these trends are expected to persist through the year. Scott Fidel (Goldman Sachs) asked about the impact of proposed HOPPS and 340B policy changes on the ambulatory segment. Sutaria responded that the company is still evaluating potential effects and will provide more details once the regulatory landscape is clearer. Brian Tanquilut (Jefferies) inquired whether Tenet’s volume strength indicated market share gains. Sutaria pointed to portfolio restructuring, capital investment in growth markets, and demographic trends as factors behind healthy volume and margin returns. In the quarters ahead, the StockStory team will be closely monitoring (1) progress on Tenet’s ambulatory acquisition pipeline and integration of high-acuity service lines, (2) the pace and sustainability of margin gains from technology-enabled cost management, and (3) the company’s ability to manage payer mix shifts and exchange enrollment headwinds. Regulatory updates to reimbursement models and further clarity on Medicaid and 340B policies will also be key signposts. Tenet Healthcare currently trades at $259.56, up from $199.02 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members). ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.

The Ensign Group, Inc. ENSG reported a second-quarter 2026 adjusted EPS of $1.92, which beat the Zacks Consensus Estimate by 6.7%. The bottom line improved 20.8% year over year. Operating revenues advanced 17.3% year over year to $1.4 billion. The top line beat the consensus mark by 0.6%. ENSG’s strong results were driven by higher occupancy, improved patient days and contributions from acquired and transitioning facilities, along with growth in rental income. The positives were partly offset by higher expenses. The Ensign Group, Inc. price-consensus-eps-surprise-chart | The Ensign Group, Inc. Quote Ensign Group’s adjusted net income of $114.3 million rose 22.5% year over year. Same-facilities occupancy improved 220 basis points (bps) to 84.1%, while transitioning-facilities occupancy increased 190 bps year over year to 84.7%. Total expenses escalated 17.3% year over year to $1.3 billion due to higher cost of services, rent and G&A costs and came in higher than our estimate by 0.6%. Skilled Services: The segment’s revenues totaled $1.4 billion, which grew 17.6% year over year but missed our estimate by 1.2%. The metric benefited from higher occupancy rates and improved patient days. Segment income of $179.6 million advanced 19.7% year over year. Skilled nursing facilities and campus operations were 348 and 32, respectively. Standard Bearer: Rental revenues climbed 40.2% year over year to $44.1 million in the quarter. The metric benefited from real estate purchases and increased annual rent. Segment income of $12.1 million advanced 32.3% year over year. Funds from operations amounted to $24.7 million, which increased 34.6% year over year. Ensign Group exited the second quarter with cash and cash equivalents of $262.3 million, which fell from the 2025-end figure of $503.9 million. It had $591.6 million of available capacity under its line of credit. Total assets of $5.7 billion increased from $5.5 billion at the end of 2025. Long-term debt — less current maturities — totaled $135.6 million, down from $137.5 million as of Dec. 31, 2025. Current maturities of long-term debt amounted to $4.2 million. Total equity of $2.4 billion advanced from the 2025-end figure of $2.2 billion. ENSG generated net cash from operations of $272.1 million in the first half of 2026, which grew from the prior-year figure of $228 million. ENSG bought back shares worth $40 million in the second quarter of 2026. As of June 30, 2026, $60 million remained available under the company’s stock repurchase program. The company also paid a quarterly cash dividend of 6.5 cents per share of Ensign common stock. ENSG has raised its full-year 2026 outlook. Revenues are now expected to range between $5.87 billion and $5.92 billion compared with the prior guidance of $5.81-$5.86 billion. Adjusted EPS is projected to be in the band of $7.75-$7.85 per share, up from the earlier estimate of $7.48-$7.62. The weighted average common shares outstanding is currently estimated to be around 59.5 million and the tax rate is anticipated to be 25%. ENSG currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation THC, Elevance Health, Inc. ELV and UnitedHealth Group Incorporated UNH. Here's how they have performed: Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions. Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. ELV’s quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The gains were partly offset by a decline in overall medical membership and higher operating expenses. UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. UNH’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Humana Inc. HUM reported second-quarter 2026 adjusted earnings of $7.61 per share, which beat the Zacks Consensus Estimate by 22.4%. The bottom line rose 21.4% year over year. Adjusted revenues improved 26.2% year over year to $40.9 billion. The top line surpassed the consensus mark by 0.6%. The strong quarterly results benefited on the back of premium gains and a robust performance from the CenterWell segment, which saw a revenue jump supported by its primary care business. A rise in overall medical membership also contributed to the upside. However, the upside was partly offset by escalating operating expenses and a deteriorating benefit ratio. Humana Inc. price-consensus-eps-surprise-chart | Humana Inc. Quote Humana’s premiums totaled $38.8 billion, which advanced 26.4% year over year, and surpassed the Zacks Consensus Estimate of $38.6 billion and our estimate of $38.1 billion. Services revenues rose 27.1% year over year to $1.8 billion, beating the consensus mark of $1.7 billion. Investment income of $253 million fell 7% year over year in the quarter under review. However, the metric beat the consensus mark of $235.3 million and our estimate of $241.9 million. The benefit ratio came in at 91.1%, which deteriorated 140 basis points (bps) year over year. Total operating expenses increased 26.3% year over year to $39.5 billion, higher than our estimate of $38.9 billion. The year-over-year increase was due to higher benefits and operating costs. The adjusted operating cost ratio of 9.7% improved 120 bps year over year. HUM’s net income increased 27.6% year over year to $693 million but beat our estimate of $562.1 million. The segment’s revenues rose 25.9% year over year to $39.1 billion in the second quarter on the back of improved per-member premiums derived from HUM’s Medicare and stand-alone PDP businesses, supported by improved Medicare Advantage benchmark funding from the Centers for Medicare and Medicaid Services and a higher Part D direct subsidy tied to the IRA. Adjusted operating income grew 7% year over year to $824 million. The benefit ratio deteriorated 130 bps year over year to 91.2%. The operating cost ratio of 7.1% improved 120 bps year over year. Total medical membership of the segment was 17.9 million as of June 30, 2026, which rose 20.7% year over year. The metric beat the Zacks Consensus Estimate of 17.5 million and our estimate of 17 million. The unit recorded revenues of $6.8 billion in the quarter under review, which improved 22.6% year over year and surpassed the Zacks Consensus Estimate of $6.3 billion. The metric benefited from higher revenues stemming from the company’s primary care business. Adjusted operating income rose 27.2% year over year to $514 million. The operating cost ratio of 92.4% improved 30 bps year over year, driven by the ongoing maturation of the v28 risk model update within the company’s primary care business and its cost-cutting and transformation strategy. Humana exited the second quarter with cash and cash equivalents of $6.9 billion, which rose 64.1% from the 2025-end level. Total assets of $57.2 billion increased 16.9% from the figure at 2025-end. Long-term debt amounted to $12 billion, down 3.2% from the figure as of Dec. 31, 2025. Debt to capitalization deteriorated 200 bps year over year to 42.7% at the second-quarter end. Total stockholders’ equity of $19.3 billion advanced 8.8% from the 2025-end figure. HUM generated net cash from operations of $3.2 billion in the first half of 2026, which more than doubled year over year. Humana bought back shares worth $108 million in the first half of 2026. It also paid dividends of $214 million during the same period. Revenues are still projected to be a minimum of $160 billion, which implies a 23.4% increase from the 2025 reported figure. The Insurance segment’s revenues are expected to continue to be forecasted at a minimum of $155 billion. Revenues of the CenterWell segment are still expected to be at a minimum of $25 billion. Adjusted EPS is still projected to be at least $9, which indicates a 47.5% decline from the 2025 figure. GAAP EPS is now projected to be at least $6.52, down from the previously expected guidance of at least $8.36. Management still anticipates Individual Medicare Advantage membership to witness growth of around 25% in 2026. Group Medicare Advantage membership is still expected to record an increase of roughly 150,000. Membership from the Individual Medicare stand-alone PDP is still expected to increase around 1,000,000 this year. State-based contracts are still anticipated to witness membership growth within 25,000-100,000. The GAAP benefit ratio for the Insurance segment is still likely to be 92.75%, with a variability margin of plus or minus 25 basis points. The GAAP consolidated adjusted operating cost ratio is still expected to be at 10%, with a variability margin of plus or minus 25 basis points. GAAP cash flow from operations is still estimated within $2.5-$2.9 billion. Meanwhile, capital expenditures are still projected to be roughly $650 million. The adjusted effective tax rate is expected to be around 25.5%, while the weighted average share count is anticipated at around 121 million. HUM currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation THC, Elevance Health, Inc. ELV and UnitedHealth Group Incorporated UNH. Here's how they have performed: Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions. Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. ELV’s quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The gains were partly offset by a decline in overall medical membership and higher operating expenses. UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. UNH’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Acadia Healthcare Company, Inc. ACHC reported adjusted second-quarter earnings of 38 cents per share, which beat the Zacks Consensus Estimate by 15.2%. However, the bottom line declined 54% year over year. Total revenues declined 0.4% year over year to $865.8 million. The top line surpassed the Zacks Consensus Estimate by 2.5%. The better-than-expected quarterly results reflected strong patient demand, as admissions increased and same-facility patient days improved. Residential Treatment Facilities also delivered double-digit revenue growth. However, lower revenue per patient day, a shorter average length of stay and higher operating expenses weighed on profitability. Acadia Healthcare Company, Inc. price-consensus-eps-surprise-chart | Acadia Healthcare Company, Inc. Quote Acute Inpatient Psychiatric Facilities revenues totaled $494.6 million, which remained flat year over year but beat the Zacks Consensus Estimate by 4.3%. Specialty Treatment Facilities' revenues declined 8.4% year over year to $133.5 million. Comprehensive Treatment Facilities revenues amounted to $141.2 million, flat year over year. Residential Treatment Facilities revenues increased 11.6% to $96.5 million. Same-facility revenues of $856.4 million edged down 0.1% year over year but beat the Zacks Consensus Estimate by 3.6%. Patient days increased 0.8%, while revenue per patient day declined 0.8%. Admissions grew 6.4% year over year. The average length of stay decreased 5.3% year over year and missed the consensus estimate by 3.2%. Overall facility patient days remained flat year over year, while admissions increased 6.3%. Revenue per patient day declined 0.4% year over year, and the average length of stay decreased 5.9%. Total operating expenses increased 7.3% year over year to $727.6 million, primarily due to higher salaries, wages and benefits, professional fees, supplies and other operating expenses. Total adjusted EBITDA declined 26% year over year to $149.2 million. During the quarter, the company added 240 licensed beds from newly constructed facilities. Acadia Healthcare exited the second quarter with cash and cash equivalents of $171.3 million, which increased from the 2025-end level of $133.2 million. It had remaining borrowing capacity of $669.8 million under its $1 billion revolving credit facility at the end of the second quarter. Total assets of $5.5 billion increased 0.3% from the 2025-end figure. Long-term debt amounted to $2.4 billion, which declined from $2.5 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million. Total equity of $2 billion increased from the 2025-end level of $1.9 billion. Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period. The company did not buy back shares in the second quarter of 2026. Acadia Healthcare updated its 2026 guidance. The company now expects revenues to be in the range of $3.40-$3.45 billion compared with the previous guidance of $3.37-$3.45 billion. Adjusted EBITDA is now projected to be in the band of $590-$615 million compared with the previous outlook of $580-$615 million. Adjusted EPS is now expected to be $1.45-$1.60 compared with the earlier guidance of $1.35-$1.60. Management also raised its operating cash flow forecast to $350-$400 million from $285-$325 million. Capital expenditures are now expected to be $235-$255 million, down from the prior guidance of $255-$280 million. Management previously guided for the addition of 400-600 licensed beds in 2026. Acadia Healthcare currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Here are some stocks from the broader Medical space that have also reported their quarterly results: Tenet Healthcare Corporation THC, UnitedHealth Group Incorporated UNH and Universal Health Services, Inc. UHS. Here's how they have performed: Tenet Healthcare reported second-quarter 2026 adjusted earnings per share of $6.12, which surpassed the Zacks Consensus Estimate by 50%. The bottom line increased 52.2% year over year. THC’s net operating revenues advanced 6.8% year over year to $5.63 billion. The top line surpassed the consensus mark by 4.4%. The quarterly results were driven by strong same-facility revenue growth, higher patient acuity, disciplined expense management and higher Medicaid supplemental revenues. However, the gains were partly offset by an unfavorable payer mix due to lower exchange admissions. UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. The top line beat the consensus mark by 1.7%. UNH’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains. Universal Health Services reported second-quarter 2026 adjusted earnings per share of $5.98, which beat the Zacks Consensus Estimate by 5.7%. The bottom line rose 10.1% year over year. Net revenues of $4.6 billion improved 8.3% year over year. The top line beat the consensus mark by 2.6%. UHS’ strong quarterly results were driven by healthy revenue growth across both the Acute Care and Behavioral Health segments. Higher adjusted admissions, increased patient days and improved unit revenues on a same-facility basis supported performance in both businesses. However, the upside was partly offset by elevated operating costs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research